Samsung Bioepis
Biopharmaceutical company focused on development, manufacture and commercialization of biosimilar and novel biologic therapeutics. Operates R&D and regulatory programs across multiple therapeutic areas (immunology, oncology, ophthalmology, hematology, nephrology, endocrinology), pursues partnerships for global commercialization, and publishes market and policy analysis. Publicly reports ESG and quality-management activities including ISO certifications and a commitment to renewable energy initiatives.
Industries
Nr. of Employees
large (251-1000)
Samsung Bioepis
Incheon, Inch'on-jikhalsi, South Korea, Asia
Products
Portfolio of biosimilar therapeutics
A portfolio of biosimilar monoclonal antibodies and protein biologics across immunology, oncology, ophthalmology, hematology, nephrology and endocrinology with multiple regulatory approvals across global markets.
Portfolio of biosimilar therapeutics
A portfolio of biosimilar monoclonal antibodies and protein biologics across immunology, oncology, ophthalmology, hematology, nephrology and endocrinology with multiple regulatory approvals across global markets.
Services
Global commercialization and licensing
Partnering for regional commercialization, licensing and market access for biologic therapeutics.
Co-development of oncology ADCs
Collaborative R&D and licensing for development and manufacturing of bispecific and dual-payload ADC therapeutics.
Market research and biosimilar market reporting
Quarterly market reports and analysis on biosimilar approvals, launches, pricing and policy impacts.
Global commercialization and licensing
Partnering for regional commercialization, licensing and market access for biologic therapeutics.
Co-development of oncology ADCs
Collaborative R&D and licensing for development and manufacturing of bispecific and dual-payload ADC therapeutics.
Market research and biosimilar market reporting
Quarterly market reports and analysis on biosimilar approvals, launches, pricing and policy impacts.
Expertise Areas
- Biosimilar development
- Biologic therapeutics and ADC development
- Clinical trial management
- Regulatory submissions and global approvals
Key Technologies
- Monoclonal antibody therapeutics
- Antibody-drug conjugates (ADCs)
- Mammalian cell culture and bioprocessing
- Protein bioassays and physicochemical characterization